from Kaiser Health News http://ift.tt/2m1pmzc
Related Posts:
Doctores sopesan pros y contras de recetar la nueva droga para el AlzheimerMientras médicos y expertos en políticas de salud debaten los méritos de Aduhelm, el primer fármaco para el Alzheimer aprobado en 18 años, los pacientes simplemente quieren saber: “¿me ayudará?”.
Los médicos no tienen una res… Read More- Drugmakers’ Spending on Stock, Dividends and Executive Pay Exceeds Research, Democrats SayThe largest drug companies are far more interested in enriching themselves and investors than in developing new drugs, according to a House committee report released Thursday that argues the industry can afford to charge Medi… Read More
- Doctors Weigh Pros and Cons of Prescribing Hot-Button Alzheimer’s DrugAs physicians and health policy experts debate the merits of Aduhelm, the first new drug for Alzheimer’s disease approved in 18 years, patients want to know: “Will this medication help me — and how much?”
Doctors explaining t… Read More
- Effort to Decipher Hospital Prices Yields Key Finding: Don’t Try It at HomeA federal price transparency rule that took effect this year was supposed to give patients, employers and insurers a clearer picture of the true cost of hospital care. When the Trump administration unveiled the rule in 2019, … Read More
- Federal Speech Rulings May Embolden Health Care Workers to Call Out Safety IssuesKaren Jo Young wrote a letter to her local newspaper criticizing executives at the hospital where she worked as an activities coordinator, arguing that their actions led to staffing shortages and other patient safety problems… Read More
January 05, 2018
Rose
January 05, 2018
Rose
Health News, Kaiser Health News
No comments
0 comments:
Post a Comment